Volonaut Airbike: Bizarre flying Star Wars bike becomes reality
It looks like something straight out of a scene from Star Wars — but it's real, it flies, and it could change how we travel.
Volonaut's flying motorbike, a futuristic single-occupant vehicle, has given us a glimpse into what the future could look like when people start effortlessly gliding the streets.
The project has been in 'stealth mode,' and it's only now that we've been able to see its full potential. The Volonaut Airbike has already captured global attention for its futuristic design and spectacular flying abilities.
Footage shared by the company on YouTube shows the hoverbike handling forest ridge lines and dry lakebeds with little difficulty while lifting and landing without assistance.
According to Volonaut, the 'superbike for the skies' is powered by a jet propulsion system that can carry one person and reach speeds up to 200km/h.
That's seriously impressive if true.
The bike features a unique riding position with an unobstructed 360-degree view, designed to help the rider quickly feel at one with the flying machine.
The contraption has no enclosure caging the rider and no seatback, which means whoever flies this thing will have to lean to the front MotoGP style.
The Airbike's extremely compact design and absence of spinning propellers allow it to travel through most confined areas with ease.
Specifics about the jet propulsion technology have not been disclosed.
The company also claims its proprietary stabilisation system — powered by an on-board flight computer — enables automatic hovering and smooth, intuitive control.
The Airbike is seven times lighter than a typical motorcycle thanks to the use of advanced carbon fibre materials, 3d printing, and a minimalistic approach.
We've seen multiple attempts at flying cars from companies like XPeng and AMSL Aero, but this takes it to the next level, pushing the boundaries of what we thought was only possible in fiction movies.
The start-up company's hoverbike quickly garnered enthusiasm from many individuals online.
On the company's YouTube channel, one user expressed their excitement by commenting, 'I am so ready for this. Already bought the full body cast.'
Another user exclaimed, 'Oh my God, we got the oppressor mark 2 in real life before GTA 6!'
While the overall response was positive, some individuals raised concerns about safety and noise
.
One user remarked, 'This thing has to be LOUD!!!!' Another explained, 'I'm a tow truck driver; people can barely drive cars. This thing is gonna be so dangerous.'
A different user noted, 'You don't have to hide the fact that this thing is extremely loud when flying,' and continued, 'It's obviously using a powerful jet engine and would be fantastic to hear it roaring through a scenic landscape.'
The creator behind the Volonaut Airbike is Tomasz Patan, a man with a vision for creating futuristic electrical vertical takeoff and landing (eVTOL) concepts.
Tomasz has been described as an 'engineering genius' and was founder and technical engineer at left-field flying machine company Jetson.
In March, the Jetson ONE's first production model successfully completed its maiden flight, demonstrating impressive stability and a smooth landing — traits shared by the new Airbike.
While the Airbike's design and capabilities have generated excitement, Volonaut has yet to announce pricing or a release date. However, the fact that the Airbike has already been tested in flight shows the momentum building behind personal air mobility.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
SBS Australia
2 days ago
- SBS Australia
The Australian first which could save thousands worldwide
An Australian company has achieved the "holy grail" of landmine detection, developing technology which it says can definitively tell if hidden explosives lie underground. Those looking to build technology capable of scanning for explosives — rather than for the metal in landmines — have searched for a solution for more than two decades, Nick Cutmore of tech company MRead said. Around 6,000 people are killed and wounded every year by landmines, despite the international adoption of the Ottawa Mine Ban Treaty nearly three decades ago. Cutmore, the firm's chief technology officer, said the company has developed a device similar to a metal detector but uses magnetic resonance to detect explosive compounds. "[There's] nothing around in current technology that can look into the ground and tell you that there's absolutely explosive there and count the number of explosive molecules present," he said. "That's exactly what we do." "The closest analogy that you could think of in your daily life is the MRI scan in a hospital, where you basically have radio waves going into you as the object and the radio waves that come back help to form the image of that scan. We do something similar," Cutmore said. Landmine clearance operations are slow, and current devices typically detect metal, leading to hundreds of false positives, as former battlefields are also littered with shrapnel, debris and other metal. Many mines are now made from plastic, partly because it's difficult to detect. Trials for the MRead technology took place in Angola on the same minefields that Princess Diana visited in the 1990s. Conducted in collaboration with demining organisation The HALO Trust, the trials demonstrated the device's ability to detect the explosive compound RDX. But the team was only halfway there. TNT, the most common explosive used in landmines, was successfully identified in laboratory testing in Australia last month — a major breakthrough. Bruce Edwards, head of partnerships at The Halo Trust, said, "I'm a big fan of saying there is no silver bullet in our work, and people ask about game changers all the time." "If we can have a detector that does detect both RDX and TNT within metal and plastic mines, then this has got to be close to a game changer. " The team hopes the lab results will translate to reality. A new prototype that can detect both TNT and RDX, explosives believed to be found in 90 per cent of mines globally, is now in development, with active minefield trials expected to start in 2026. Edwards said: "As I said, no silver bullet, but definitely a breakthrough. It is exciting. Absolutely. And as an Australian, I've got to say, it is quite nice to have this Australian contribution being made across the world and I'd love to see them in Ukraine." Ukraine is now believed to be the most dangerous place on Earth for unexploded weapons. It's estimated millions of explosives have been strewn across battlefields in Ukraine since Russia's invasion in 2022. Almost a quarter of the country is at risk of contamination, and it could take decades to eliminate these invisible threats from the land. Edwards, who is now based in Mykolaiv, is the former Australian Ambassador to Ukraine, said: "Our CEO has described landmines as the 'eternal vigilant sentry' and no better is that demonstrated in the likes of Angola, one of our largest programs. "In Cambodia, in Afghanistan, Sri Lanka ... still we're seeing deaths and inaccessibility due to these wars that for many people will be far, far from their memory."
News.com.au
4 days ago
- News.com.au
Brisbane to trial AI traffic technology
Brisbane Council is expected to launch a $15 million trial that will result in AI technology taking over traffic signals next year. The Smarter Suburban Corridors trial was an LNP election promise and could deliver time savings of more than 20 per cent. Brisbane Lord Mayor Adrian Schrinner hopes the technology will allow the city to cope with the extra 400,000 residents expected to come in the next two decades.
News.com.au
5 days ago
- News.com.au
Health Check: Optiscan perfects ‘dial a pathologist' platform; 4D Medical probes further FDA approval
Optiscan's telepathology streaming software enables surgeons to have secure real-time access to pathologists – no matter where they are in the world 4D Medical's device probes the lung's innards without the nasties Painchek signs a US distributor ahead of expected US approval Optiscan (ASX:OIL) and its Canadian tech partner Prolucid Technologies have advanced telepathology streaming software enabling a surgeon to seek the counsel of a remote pathologist during an operation. And that could be very remote. The software has advanced to minimum viable product stage: when a product meets the minimum use requirements but can be tweaked further. The cloud-based software enables pathologists to review high-resolution images, generate reports and collaborate within secure settings. The software 'essentially brings the pathologist into the heart of the operating theatre and bridges the gap between surgery and pathology,' says Optiscan CEO Dr Camile Farah. 'This platform is a potential game changer for global digital pathology, with particular relevance to regional, rural and remote healthcare settings where access to pathology expertise is limited.' Eliminating microscopes Naturally, the software is compatible with Optiscan's medical devices, which are based on the company's proprietary confocal laser endomicroscopy, or CLE. CLE eliminates the age-old and unreliable method of analysing tissue samples under a traditional microscope. The magic involves a single optical fibre in a probe projecting laser light on to live tissue treated with fluorescent dye. This creates real-time digital microscopic images at a magnification 1000 times that of computed tomography or magnetic resonance imaging scanning. CLE avoids the need for painful biopsies. Optiscan is carrying out a 50-patient breast cancer trial at the Royal Melbourne Hospital and Frances Perry House. This is in view of an eventual US Food & Drug Adminstration (FDA) approval submission. The telepathology project now will focus on validating the platform in real-world uses, incorporating user feedback and 'preparing for broader clinical deployment'. Optiscan shares surged 13% this morning. 4D Medical vies for a further FDA approval 4D Medical (ASX:4DX) CEO Dr Andreas Fouras says the lung imaging house has a 'once in a generation' opportunity to improve healthcare with its latest tool subject to FDA perusal. "We have an incredible opportunity whereby existing lung diagnostics are failing us," Fouras told an investor webinar this morning. 4D yesterday said it had lodged a marketing approval application for its software, which probes the innards of the lungs as an adjunct to computed tomography (CT) scans. The key selling point of the CT:VQ software is that it enables data and visualisations to be extracted from a routine CT scan, without the need for any radiotracer or contrast agent. VQ scans evaluate both the airflow (ventilation) and blood flow (perfusion) in a patient's lungs. We're not sure why they are known as 'VP' scans, but let's move on. The CT:VQ test creates images that show how well air and blood are distributed throughout the lungs. This helps doctors identify areas where there might be an imbalance between ventilation and perfusion. Fouras said existing methods were logistically challenging, slow and expensive. The most widely used, a single camera scan called planar scintigraphy produces grainy and flat images. VQ scans diagnose several lung conditions, including primarily pulmonary embolism (blood clots in the lungs), chronic thromboembolic pulmonary hypertension, chronic obstructive pulmonary disease and asthma. The current process consists of two scans. These are a ventilation component involving inhaling a material with contrast agent, followed by injection of a radioactive contrast to assess blood flow. Fouras said one million VQ scans were done in the US annually 'and we intend to capture every one of them.' In old naval parlance, that's known as a clean sweep. Burgeoning US portfolio If CT:VQ is approved, 4D Medical will have nine cleared products in the US, as well as six each in Europe and Australia. Fouras notes the company's lung ventilation analysis software tool LVAS attracts public reimbursement of UD$650 ($1000) per scan. He reckons CT:VQ should fit neatly into this code. CT:VQ is subject to an ongoing 80-participant study of lung health with the US Department of Defense. Under the FDA's protocols, the agency decided within 90 days. But this typically extends to 120 days accounting for follow-up review time with the applicant. 4D shares surged 17% after Monday's announcement but were a tad off today. Painchek lines up US distributor The developer of the world's first mobile phone-based pain assessment and monitoring tool, PainChek (ASX:PCK) has signed up a US distributor ahead of anticipated FDA approval in the current quarter. Painchek already has a dominant share of the Australian aged-care market with its eponymous device and a substantial UK beachhead as well. But as is the norm, the US offers the greatest opportunity. The company cites a local market of 220,000 aged-care beds and 540,000 in the UK, equating to an annual value of $11 million and $26 million annually. But the US has 1.7 million beds, for an annual value of $100 million. Painchek's non-exclusive agreement is with Eldermark Software, which provides care management systems in the US (and Canada) to more than 116,000 clients. Using facial recognition and AI, the device detects pain in patients unable to enunciate their discomfort, such as dementia suffers. Painchek also has its eyes on the larger, 400 million strong pre-verbal kids' market. 'The financial impact cannot be quantified at the time of entry into the agreement, as it is a reseller agreement based on Eldermark's best efforts to promote Painchek's technology within its existing client base,' Painchek says. Elsewhere, to date, Painchek has signed contracts up with around 1800 aged care facilities, with more than ten million pain assessments carried out to date. Neuren chair decries weak share price Neuren Pharmaceuticals (ASX:NEU) chairman Patrick Davies says he is 'frustrated and disappointed' by the company's marked-down share price that not reflect the company's success with its approved US Rett syndrome drug, Daybue. Addressing the company's AGM this morning, Davies said Neuren had hauled in $445 million of royalties from its partner Acadia in 2023 and 2024 – in effect pure profit. Neuren shares have declined from their $25 peak in late 2023, to as low as $8.70 in mid-April. While the shares have improved since, management contends the $1.7 billion market cap hardly reflects Neuren's progress across at least three other add-on indications. One of them – for Phelan-McDermid syndrome – is entering phase III stage. Neuren's cash has swelled to $341 million. 'It was only a few years ago that we had to work really hard to raise fresh capital of $20 million to support our growth plans,' Davies says.
